Lazard Asset Management LLC grew its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 341.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 596,389 shares of the biotechnology company's stock after buying an additional 461,430 shares during the quarter. Lazard Asset Management LLC owned 0.42% of Aurinia Pharmaceuticals worth $5,355,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $25,000. Tower Research Capital LLC TRC grew its holdings in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,635 shares in the last quarter. Natixis purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $49,000. Blue Trust Inc. grew its holdings in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after buying an additional 6,174 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at $90,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Stock Performance
NASDAQ AUPH traded up $0.18 during trading hours on Tuesday, hitting $8.25. The company had a trading volume of 631,279 shares, compared to its average volume of 1,379,551. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a 1-year low of $5.11 and a 1-year high of $10.67. The company has a market cap of $1.11 billion, a PE ratio of -55.13 and a beta of 1.16. The business has a 50 day moving average of $8.02 and a 200-day moving average of $8.26.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.08 by $0.08. The company had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. As a group, equities research analysts expect that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.
Analyst Ratings Changes
Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.
Check Out Our Latest Analysis on Aurinia Pharmaceuticals
Insider Activity
In related news, insider Greg Keenan sold 8,305 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,898 shares of company stock valued at $2,753,094. Company insiders own 4.30% of the company's stock.
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
